RPG Life Sciences Limited (RPGLIFE.BO)
RPG Life Sciences Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Mumbai, MA, IN. The stock last traded at $2774.60, down 1.64% on the session, giving a market capitalisation of $46.24B. Its beta of -0.21 implies it has historically moved less than the broad market.
RPG Life Sciences Limited operates as a comprehensive pharmaceutical entity, engaged in the creation, production, and sale of branded drug formulations, generic medicines, and synthetic active pharmaceutical ingredients (APIs) both within India and across global markets. Their portfolio of synthetic APIs spans diverse therapeutic fields, encompassing treatments for conditions such as immunosuppression, psychosis, angina, parasitic infections, seizures, and spasms, among others. The company primarily supplies generic medications for immunosuppressant conditions, alongside a broad range of finished dosage formulations targeting numerous health issues. Its therapeutic reach extends to a vast number of medical areas, including nephrology, rheumatology, oncology, gastroenterology, cardiovascular, orthopedics, respiratory, neurology, urology, diabetes management, dengue fever, nutritional supplements, gynecology, and pediatrics, among many others. Initially established as RPG Pharmaceuticals Limited, the organization rebranded to RPG Life Sciences Limited in February 2008. Founded in 1968, this Mumbai, India-headquartered firm functions as a subsidiary under the Nucleus Life Trust.
RPG Life Sciences Limited is most often compared with the following Healthcare names: